iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200
Debt
Debt-to-Equity Ratio0.42
Current Ratio1.50
Quick Ratio1.33
Price-To-Earnings
Trailing P/E Ratio-4.82
Forward P/E Ratio-5.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.10 million
Price / Sales1.74
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book3.42
Profitability
EPS (Most Recent Fiscal Year)($0.61)
Net Income$-14,250,000.00
Net Margins-61.83%
Return on Equity-59.65%
Return on Assets-30.38%
Miscellaneous
Employees119
Outstanding Shares16,660,000
Market Cap$48.32 million
iCAD (NASDAQ:ICAD) Frequently Asked Questions
What is iCAD's stock symbol?
iCAD trades on the NASDAQ under the ticker symbol "ICAD."
How were iCAD's earnings last quarter?
iCAD Inc (NASDAQ:ICAD) released its earnings results on Tuesday, August, 14th. The technology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The technology company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.84 million. iCAD had a negative return on equity of 59.65% and a negative net margin of 61.83%. View iCAD's Earnings History.
When is iCAD's next earnings date?
Who are some of iCAD's key competitors?
Some companies that are related to iCAD include Apollo Endosurgery (APEN), Alphatec (ATEC), Sensus Healthcare (SRTS), Motus GI (MOTS), Invuity (IVTY), CAS Medical Systems (CASM), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), Repro-Med Systems (REPR), SANUWAVE Health, Inc. Common Stock (SNWV), Restoration Robotics (HAIR), Nephros (NEPH) and Valeritas (VLRX).
Who are iCAD's key executives?
iCAD's management team includes the folowing people:
- Mr. Kenneth M. Ferry, CEO & Director (Age 64)
- Mr. Richard C. Christopher, Exec. VP, CFO, Treasurer & Sec. (Age 48)
- Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 50)
- Ms. Annette L. Heroux, VP of Admin. (Age 61)
- Mr. Jonathan Go, Sr. VP of R&D (Age 55)
Has iCAD been receiving favorable news coverage?
Media headlines about ICAD stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iCAD earned a news and rumor sentiment score of 0.03 on Accern's scale. They also assigned news coverage about the technology company an impact score of 49.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for iCAD.
Who are iCAD's major shareholders?
iCAD's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Argent Capital Management LLC (1.23%). Company insiders that own iCAD stock include Dr Lawrence Howard and Kenneth M Ferry. View Institutional Ownership Trends for iCAD.
Which major investors are selling iCAD stock?
How do I buy shares of iCAD?
Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iCAD's stock price today?
One share of ICAD stock can currently be purchased for approximately $2.94.
How big of a company is iCAD?
iCAD has a market capitalization of $48.32 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe.
How can I contact iCAD?
iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]
MarketBeat Community Rating for iCAD (NASDAQ ICAD)
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
